Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis

International Ophthalmology

Volumn 28, Issue 4, 2008, Pages 311-316

  Ben Yahia, Salim ^a   Herbort, Carl P ^b,c   Jenzeri, Salah ^a   Hmidi, Kamel ^a   Attia, Sonia ^a   Messaoud, Riadh ^a   Khairallah, Moncef ^a  

^a FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^b Centre for Ophthalmic Specialized Care COS   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Bevacizumab; Choroidal neovascularization; Ocular toxoplasmosis; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; EYE EXAMINATION; EYE FUNDUS; FEMALE; FOLLOW UP; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TOXOPLASMOSIS; VISUAL ACUITY; VISUAL DISORDER;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INJECTIONS; TOMOGRAPHY, OPTICAL COHERENCE; TOXOPLASMOSIS, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 47949124904     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-008-9218-2     Document Type: Article

References (10)

1. Adan A, Mateo C, Wolley-Dod C (2003) Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis. Am J Ophthalmol 135:386-387
2. Wirthlin R, Song A, Song J, Rosenfeld PJ (2006) Verteporfin photodynamic therapy of choroidal neovascularization secondary to ocular toxoplasmosis. Arch Ophthalmol 124:741-743
3. Perentes Y, Van Tran T, Sickenberg M, Herbort CP (2005) Subretinal neovascular membranes complicating uveitis: Frequency, treatments and visual outcome. Ocul Immunol Inflamm 13:219-224
4. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372
5. Laud K, Spaide RF, Freund KB et al (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960-963
6. Teixeira A, Moraes N, Farah ME, Bonomo PP (2006) Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand 84:835-836
7. Kwak N, Okamoto N, Wood JM, Campochiaro PA (2000) VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158-3164
8. Perentes Y, Chan CC, Bovey E, Uffer S, Herbort CP (2002) Massive vascular endothelial growth factor (VEGF) expression in Eales' disease. Klin Monatsbl Augenheilk 219:11-14
9. Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262-269
10. Adan A, Mateo C, Navarro R et al (2007) Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27:1180-1186